For subscribers
Why China biotech is getting a DeepSeek moment too
The country is emerging as an attractive place for Big Pharma to chase billion-dollar licensing deals.
Sign up now: Get ST's newsletters delivered to your inbox
Workers working at a Sinovac Covid-19 vaccine production line in Beijing in 2021. So far, the biotech industry is relatively insulated from Mr Trump’s tariffs.
PHOTO: XINHUA
Shuli Ren
Follow topic:
From artificial intelligence to military defence, China has offered a few DeepSeek moments in 2025, showcasing that the country is more than just the world’s biggest factory, and that it also can compete with the US on the technology front. Now biotech is having its own.
In late May, Pfizer agreed to pay a record US$1.25 billion (S$1.6 billion) upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol Myers Squibb said it would pay BioNTech US$1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus, the Chinese company that developed the drug, late in 2024 for US$800 million.
